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Abstract
Background: Inherited thrombocytopenias (ITs) are a heterogeneous group of disor-
ders characterized by low platelet counts and often disproportionate bleeding with 
over 30 genes currently implicated. Previously the UK- GAPP study using whole 
exome sequencing (WES) identified a pathogenic variant in 19 of 47 (40%) patients of 
which 71% had variants in genes known to cause IT.
Aims: To employ a targeted next-generation sequencing platform to improve effi-
ciency of diagnostic testing and reduce overall costs.
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1  | INTRODUCTION
Inherited thrombocytopenias (ITs) are a heterogeneous group of dis-
orders characterized by a sustained reduction in platelet count often 
manifesting as a bleeding diathesis. Since the discovery of disease 
inheritance patterns in disorders such as Bernard Soulier Syndrome 
(BSS), genetic studies of thrombocytopenia have been a vital tool in 
determining megakaryocyte and platelet physiology.1 As a result of 
parallel whole exome and whole genome sequencing over the past 
5- 10 years, we are discovering increasing numbers of novel genes 
and variants with a critical role in platelet production, physiology, 
and function.2–5
To date, there are 30 genes suspected to cause 26 separate 
forms of inherited thrombocytopenia making genetic diagnosis com-
plex.6 However, until recently, IT remained underdiagnosed with 
previous studies only providing a genetic diagnosis in just over 50% 
of individuals.7–9 A genetic diagnosis provides clinical benefits for 
the patients. Some patients with a reduced platelet count have had 
unnecessary treatments and procedures such as immunosuppres-
sion and splenectomies and therefore establishing that they have an 
inherited component to their disease etiology would prevent this. In 
the case of suspected ITP this may be treated with steroids or immu-
nosuppressive drugs with many side effects. Therefore, if such pa-
tients are proven to have an inherited thrombocytopenia, then these 
treatments are unnecessary. Some of the gene mutations in patients, 
eg, RUNX1, result in patients having a predisposition to hematologi-
cal malignancies and once a genetic defect is proven, the information 
can be used to monitor the patients’ hematological parameters more 
closely. These all highlight the need for a definitive genetic diagnosis 
and development of a targeted gene- specific sequencing platform 
will provide a quick and cost effective screening for patients with IT.
As new sequencing library- capture methods are developed, the 
speed of sample preparation time is vastly reduced. Thus, the re-
cently released capture methods, Illumina Nextera Rapid Custom 
Methods: We have developed an IT- specific gene panel as a pre- screen for patients 
prior to WES using the Agilent SureSelectQXT transposon- based enrichment system.
Results: Thirty- one patients were analyzed using the panel- based sequencing, of 
which; 10% (3/31) were identified with a classified pathogenic variant, 16% (5/31) 
were identified with a likely pathogenic variant, 51% (16/31) were identified with vari-
ants of unknown significance, and 23% (7/31) were identified with either no variant 
or a benign variant.
Discussion and Conclusion: Although requiring further clarification of the impact of 
the genetic variations, the application of an IT- specific next generation sequencing 
panel is a viable method of pre- screening patients for variants in known IT- causing 
genes prior to WES. With an added benefit of distinguishing IT from idiopathic throm-
bocytopenic purpura (ITP) and the potential to identify variants in genes known to 
have a predisposition to hematological malignancies, it could become a critical step in 
improving patient clinical management.
K E Y W O R D S
bleeding, gene mutations, targeted panel sequencing, thrombocytopenia
Essentials
• Inherited thrombocytopenias are a heterogeneous group of disorders with over 30 causative genes identified to date.
• We have developed an IT-specific gene panel to screen patients using the rapid Agilent SureSelectQXT transposon-based enrichment 
system.
• Candidate gene variants were observed in previously implicated IT genes in 77% of individuals; 10% of patients had a classified 
pathogenic variant, 16% had a likely pathogenic variant, 51% had a variant of unknown significance and 23% had no or a benign 
variant.
• Accurate genetic diagnosis could improve the clinical outcome for this group of patients with disproportionate bleeding for their re-
duced platelet count.
642  |     JOHNSON et al.
Capture Enrichment and Agilent SureSelectQXT, both propose an 
improvement in sample preparation without limitations in sequence 
depth, coverage, and accuracy.10 When applied to small- scale cus-
tom gene panels, the preparation time can be reduced to one day. In 
addition, DNA input is also reduced allowing for amplification from 
<50 ng of DNA.11
Due to the high percentage of variants within known IT genes as 
identified by whole exome sequencing (WES) in a previous study,12 
and the increasing advances in custom panel next generation se-
quencing, an IT- specific next- generation sequencing (NGS) panel 
was designed and included within the UK- GAPP patient workflow. 
Incorporating a small custom panel prior to WES has the potential to 
filter out variants with a genetic etiology of disease within known IT- 
causing genes. Coupled with the Agilent SureSelectQXT transposon- 
based system of sample preparation, an increase in the efficiency 
of genetic diagnosis, as well as a reduction in the overall cost, can 
potentially be achieved.
Therefore, in this study we aimed to implement a NGS panel in 
the UK- GAPP patient workflow. The panel was designed to incor-
porate all genes known to be previously associated with IT, effec-
tively pre- screening patients before WES. The targeted panel also 
takes advantage of a rapid sample preparation technique allowing 
for quick genetic diagnosis following patient phenotyping and im-
proving overall diagnosis of recruited patients.
2  | METHODS
2.1 | Patients
Patients were recruited from participating UK hematology centers. 
All patients had a bleeding history taken at the point of examina-
tion and inclusion into the study. Most patients suffered from mild 
bleeding symptoms including cutaneous bruising, bleeding, and 
epistaxis in addition to more severe bleeding symptoms in some 
cases. Detailed patient clinical symptoms related to bleeding that 
were available are displayed in Table 1.
The UK- GAPP study was approved by the National Research Ethics 
Service Committee of West Midlands—Edgbaston (06/MRE07/36) and 
participants gave written informed consent in accordance with the 
Declaration of Helsinki. The GAPP study was registered at www.isrctn.
org as #ISRCTN 77951167 and is included in the National Institute 
of Health Research Non- Malignant Haematology study portfolio, 
(ID- 9858).
2.2 | Platelet counts and morphology
Platelet counts and morphology were measured from patients in 
whole blood using the Sysmex XN- 1000 (n = 31). The PLT- F chan-
nel was used to determine platelet counts in whole blood and the 
immature platelet fraction (IPF). Mean platelet volume (MPV) was 
determined from the impedance PLT- I channel. All samples were 
processed in tandem with travel controls.
2.3 | Platelet preparation and platelet 
function testing
This study focuses on a subset of patients with a reduction in plate-
let count. Previous studies by the UK- GAPP study group have dem-
onstrated the applicability of using light transmission aggregometry 
(LTA), including lumiaggregometry, for investigation of PRP samples 
having platelet counts exceeding 1 × 108/mL13 and an in- house flow- 
cytometry assay to assess platelet function in patients having plate-
let counts in PRP of less than 1 × 108/mL.12
2.4 | Thrombocytopenia- specific panel sequencing
A thrombocytopenia panel was designed for use as an initial NGS 
(NGS) sequencing/pre- screen before whole exome sequencing in 
collaboration with the Regional Genetics laboratory at Birmingham 
Women’s Hospital.
The panel was designed using the Agilent SureDesign v3.5.4 
(Agilent Technologies, UK) design software. The original design 
included the following 30 genes; ABCG5, ABCG8, ADAMTS13, 
ANKRD18A, ANKRD26, CYCS, FLI1, FLNA, FYB, GATA1, GFI1B, GP1BA, 
GP1BB, GP5, GP9, HOXA11, ITGA2B, ITGB3, MKL1, MPL, MYH10, 
MYH9, NBEAL2, ORAI1, RBM8A, RUNX1, SLFN14, STIM1, TUBB1, and 
WAS. The 30 genes encompassed genes previously associated with 
IT as well as some of their related genes and novel genes identified as 
being associated with thrombocytopenia as part of the GAPP study. 
This panel was applied to patients 48 to 61 (inclusive) and patients 
72 and 73, which encompass the first 16 patients that were ana-
lyzed by panel sequencing. Sequencing probes/baits were designed 
to cover the following regions: all coding exons ±10 bp flanking se-
quence from the intron- exon boundary and the 5′UTR and 3′UTR. 
Sequencing baits were designed with 2x density so that each desired 
region was covered by at least two overlapping probes. Baits were 
also designed with the strictest masking stringency settings pos-
sible. SureDesign masks repetitive sequences dependent on three 
masking tools: RepeatMasker, WindowMasker, and Uniqueness 35 
track. The design software uses combinations of all three tools to 
create three masking stringencies which vary in their inclusiveness 
of repeat regions. If baits could not be found in the highest strin-
gency possible, stringency was decreased until they could be found. 
Eighteen genes were covered entirely using the highest stringency 
setting, eight genes were covered by a combination of high and 
moderate stringency settings, and the remaining four genes were 
covered by baits using a combination of all three stringency settings. 
Balanced boosting of GC- rich probes was used which replicated the 
amount of probes within a GC- rich region by a defined factor to im-
prove capture of these difficult genomic fragments. The final design 
incorporated 3309 probes with an overall size of 212.189 kbp.
For subsequent sequencing beyond the first group of 16 patients 
as detailed above, an improved design was utilized to include new 
genes implicated in IT. The second version of the design included 
all probes from the first design with the addition of baits designed 
to sequence the following genes; ACTN1, ETV6, PF4, and PRKACG. 
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TABLE  1 Phenotypic symptoms of 31 patients recruited to the UK- GAPP study with IT of unknown etiology
Patient Age Gender
Platelet 
count 
(x109/l) MPV (fL) IPF (%)
Flow 
cytometry 
defect LTA defect
ATP 
secretion Bleeding phenotype
48 5 M 125 9.1 NT P- Selectin NT NT Cutaneous bruising, petechiae
49 41 M 30 NA 9.4 NT ADP Normal Cutaneous bruising
50 41 M 30 NA 59.4+ CD42b NT NT Cutaneous bleeding
51 UNK UNK 162 9.2 NT P- Selectin, 
GPVI
NT NT Cutaneous bleeding, oral cavity 
bleeding
52 43 F 131 8.7 14.7+ Normal AA Reduced Cutaneous bleeding, epistaxis, 
menorrhagia, Gi bleeding, oral 
cavity bleeding
53 27 F 104 9.1 NT Fibrinogen NT NT Cutaneous bleeding
54 12 M 101 10 39.8+ P- Selectin NT NT Cutaneous bleeding
55 UNK F 30 8.6 2.3 P- Selectin NT NT Cutaneous bruising, oral cavity 
bleeding, menorrhagia
56 15 F 48 10.2 45.2+ Normal NT NT Cutaneous bleeding, epistaxis
57 11 F 153 12.1 9.2 NT ADP, AA Reduced Cutaneous bruising/bleeding
58 9 F 82 8.6 6.4 P- Selectin, 
Fibrinogen
NT NT Cutaneous bruising/bleeding
59 4 M 94 12.3 7.1 Normal NT NT Cutaneous bruising/bleeding
60 UNK F 146 13.4+ 15.8+ CD41 Adr Normal Cutaneous bruising, oral cavity 
bleeding, menorrhagia
61 UNK F 76 9.7 3.4 P- Selectin, 
Fibrinogen
NT NT No observable phenotype
62 34 F 138 13.8+ 17.5+ Normal NT NT Cutaneous bleeding
63 13 F 37 14.6+ 16+ P- Selectin NT NT Cutaneous bruising, petechiae, 
epistaxis
64 UNK F 105 14.5+ 23.1+ NT Normal Normal Cutaneous bruising, epistaxis
65 35 F 52 14.9+ 19.4+ P- Selectin, 
Fibrinogen
NT NT Cutaneous bruising/bleeding
66 18 F 87 10 1.8 P- Selectin, 
Fibrinogen
NT NT Cutaneous bruising/bleeding
67 22 M 40 13.1+ 15.7+ NT Normal Normal Cutaneous bruising/bleeding, 
epistaxis
68 17 M 191 NT NT NT NT NT Cutaneous bleeding, nose 
bleeds
69 26 M 69 NT NT NT NT NT Nose bleeds
70 34 F 96 NT NT NT NT NT None, incidentally identified 
thrombocytopenia
71 50 M 128 NT NT NT NT NT None, investigated as son has 
thrombocytopenia
72 33 F 14 NT NT NT NT NT Cutaneous bleeding, menorrha-
gia, acute lymphoblastic 
leukemia, father died of acute 
myeloid leukemia
73 29 F 53 11.7 9.1 NT NT NT Cutaneous bruising, hematuria, 
oral cavity bleeding
74 72 M 50 8.4 NT P- Selectin NT NT Cutaneous bruising, epistaxis
75 48 F 92 NT NT NT NT NT Cutaneous bruising, hematomas
76 UNK F 92 10.2 NT Fibrinogen NT NT No observable phenotype
(Continued)
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All genes, with the exception of PRKACG, were covered by probes 
with the most stringent masking settings. Probes designed for am-
plification and sequencing of PRKACG included four probes with the 
least- stringent masking settings applied. Overall the new design in-
corporated 3447 probes covering 221.305 kbp. Target enrichment 
was performed for all designs using the Agilent SureSelectQXT NGS 
target enrichment kit for Illumina multiplexed sequencing (Agilent 
Technologies). Sample preparation followed the workflow outlined 
in the manufacturer’s instructions (Figure 1). Due to the relative 
small size of the capture library all size- related steps followed the 
methodology for capture libraries <3 Mb. In the preparation for hy-
bridization 750 ng of gDNA, diluted in a volume of 12 μL was used.
A maximum of 16 samples were prepared per run. DNA samples 
were quantified using BR and High Sensitivity (HS) Qubit dsDNA 
fluorometric quantification kits and were analyzed using a Qubit 
2.0 Fluorimeter (ThermoFisher, UK, #Q32854 for HS kit) in initial 
sample preparation. Purification steps utilized Agencourt AMPure 
XP magnetic capture beads (BeckmanCoulter, UK, #A63880). DNA 
quantity and quality was assessed at two separate points through-
out the protocol using an Agilent 2200 Tapestation system and 
associated D1000 and high sensitivity D1000 screen tape (#5067- 
5582 for D1000, #5067- 5584 for HS D1000), and reagents (includ-
ing ladder and sample buffers) (#5067- 5583 for D1000 reagents, 
#5067- 5585 for HS D1000 reagents) (Agilent Technologies). 
Dynabeads MyOne Streptavidin T1 magnetic beads were used for 
hybrid capture (ThermoFisher, #65601). Index tags were added 
using the SureSelectQXT P7 and P5 dual indexing primers. All ther-
mocycling steps were performed using a Bio- Rad DNA Engine 
Tetrad 2 Thermal Cycler (Bio- Rad, UK). Magnetic separation was 
achieved using a DynaMag- 96 Side magnet (ThermoFisher).
Samples were then pooled for multiplexed sequencing so that 
each index- tagged sample was in equimolar amounts in the pool. 
For each sample the following formula was used to determine the 
amount of index sample to use.
where V (f) = Final desired volume of pool; C (f) = Desired final con-
centration of all DNA in pool; # = is the number of the indexes; C 
(i) = Initial concentration of each sample.
A final desired volume of pool of 20 μL was used and a final con-
centration of 4 nmol/L. In all cases 16 indexes were pooled.
To achieve an optimal cluster density, a final concentration 
of 10- pmol/L DNA was used. DNA was firstly denatured by 
the addition of 5 μL of 0.2 mol/L NaOH to 5 μL of 4 nmol/L 
pooled library and allowed to incubate at room temperature 
(~20°C) for 5 minutes before adding 990 μL of pre- chilled HT1 
hybridization buffer was added to achieve a 20- pmol/L solu-
tion. A 300- μL aliquot of the 20- pmol/L solution was diluted 
with 300 μL HT1 to achieve a final concentration of 10 pmol/L 
in 600 μL.
Finally sequencing was performed using an Illumina MiSeq 
(Illumina, UK) and MiSeq v2 300 Cycle Reagent Kits (Illumina, 
#15033626). Sample sheets were designed to allow for the use of 
custom primers and no adaptor trimming. Sequencing followed a 
Nextera XT sample preparation kit and amplicon chemistry.
Sequence alignment, annotation, categorisation and variant 
calling was performed using the SureCall v3.5 software (Agilent 
Technologies) and the GenAligners 3.0 alignment tool (Agilent 
Technologies). Post aligned, annotated, and categorized sequence 
data was analyzed using a personalized bioinformatics pipeline as dis-
cussed below.
2.5 | Bioinformatics pipeline to determine 
candidate variants
Sequence data generated using the IT- specific NGS panel was ana-
lyzed using an adaptation of the pipeline developed for the analysis 
of WES data.12 Variants were initially filtered on frequency, exclud-
ing variants with a MAF ≤0.01 in the 1000- G database. Synonymous 
variants not predicted to change the amino acid sequence in the 
protein coding transcripts were then excluded. As the panel was 
designed to include the 5′ and 3′ UTRs, variants were additionally 
Volume of Index=
V(f)×C(f)
#×C(i)
Patient Age Gender
Platelet 
count 
(x109/l) MPV (fL) IPF (%)
Flow 
cytometry 
defect LTA defect
ATP 
secretion Bleeding phenotype
77 15 F 76 9.4 13.5+ Normal NT NT Oral cavity bleeding, 
menorrhagia
78 UNK M 101 13.9+ 14.4+ Normal Adr Normal Cutaneous bleeding
Average platelet count = 88 × 109/L (normal range to 2 SD 147- 327 × 109/L, n = 40). Average MPV = 11.1 fL (mean normal range to 2 SD 7.8- 12.69 fL, 
n = 40). IPF was available for 20 patients and varied between 1.8- 59.4% (normal range 1.3- 10.8%, n = 40). Patients with an observed macro and micro 
thrombocytopenia are denoted by a + and - , respectively, following their most recent analyzed MPV. Secondary qualitative defects are abbreviated to 
the following; (CD41) reduction in the resting cell surface levels of CD41, (CD42b) reduction in resting cell surface levels of CD42b, (ADP) reduction in 
response upon ADP stimulation indicating a possible defect in the Gi pathway, (AA) reduction (cyclooxygenase pathway defect), (Adr) reduction 
(Thromboxane receptor pathway defect), (GPVI) reduction in surface GPVI quantity, (P- selectin) reduction (platelet alpha- granule/secretion defect), 
(fibrinogen) reduction in the binding of fibrinogen to activated platelets, (ATP secretion) reduction in ATP secretion upon stimulation with PAR- 1 pep-
tide 100 μmol/L. Bleeding diathesis of each individual is summarized under bleeding phenotype.
AA, arachadonic acid; ADP, Adenosine diphosphate; Adr, adrenaline; ATP, Adenosine triphosphate; GPVI, Glycoprotein VI; IPF, immature platelet frac-
tion; LTA, light transmission aggregometry; MPV, mean platelet volume. + denotes an elevated MPV/IPF; NA indicates parameter was tested but results 
were inconclusive; NT indicates parameter was not tested due to degraded or limited sample; UNK indicates the parameter was not known.
TABLE  1  (Continued)
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filtered dependent on their genomic location within the coding re-
gion ±10 bp of intron- exon boundaries. The UTRs were included 
in bait design to allow detection of variants within the 5′ UTR of 
ANKRD26 so that all variants occurring within the 5′UTR of genes 
were analyzed individually. Candidate variants identified were scru-
tinized using the same in silico pathogenicity prediction software 
and variant classification system as candidates from WES analysis 
as outlined previously.12 Finally, pathogenicity of variants was de-
termined and called using the consensus guidelines as set out by 
the American College of Medical Genetics and Genomics and the 
Association for Molecular Pathology (hence forth referred to as the 
ACMG guidelines).14
2.6 | Quality of sequence data, average number of 
variants, and sequence coverage
All individual DNA samples were processed and passed QC at 
two points during sample preparation. Prior to sample pooling 
an average calibrated DNA concentration of 2.957 ng/μL and a 
molarity of 13.3 nmol/L was observed across all samples. All se-
quencing runs passed internal QC that is used within the West 
Midlands Regional Genetics Service at the Birmingham Women’s 
Hospital and internal QC from the SureCall analysis software. 
All candidate variants identified were classified as high quality 
mapped variants with a quality score of 255 using the SureCall 
software.
3  | RESULTS
3.1 | Phenotyping of IT patient cohort recruited to 
the study
All 31 unrelated cases included in this study underwent clinical 
evaluation to exclude idiopathic thrombocytopenic purpura (ITP) 
(following a relatively stable reduced platelet count over time) and 
other nonplatelet disorders including von Willebrand disease and 
inherited coagulation factor deficiencies. Subsequent analysis after 
enrolment isolated this group of patients with a suspected platelet 
count less than 150 × 109/L and therefore suspected to have an in-
herited thrombocytopenia of unknown etiology (Table 1). Platelet 
counts varied between 30 and 162 × 109/L among the 31 indi-
viduals with a mean count of 88 × 109/L (Table 1) (normal range to 
two standard deviations 147- 327 × 109/L, n = 40). Patients with a 
platelet count between 150- 200 × 109/L were retained for analy-
sis within the study under the stipulation that there was a shared 
phenotype within the patient and related affected family mem-
bers and that a prior platelet count has been below 150 × 109/L. 
Mean platelet volumes were between 8.6- 14.6 fL (n = 23) (mean for 
healthy controls ±2 SD = 7.8- 12.4 fL).The immature platelet fraction 
(IPF) mean in the patients was 17% of the total platelet count (range 
1.8- 59.4%), n = 20 (normal range 1.3- 10.8%, n = 40, mean 4.4%),the 
higher values reflecting abnormal bone marrow platelet production 
or thrombopoiesis.
F I G U R E  1 Sample preparation 
workflow for the IT- specific next- 
generation sequencing panel using Agilent 
SureSelectQXT capture methodology
gDNA samples 1,2...n
Fragment DNA and
adaptor tag DNA ends in
single enzymatic step
Adaptor-tagged DNA library
PCR amplify
Prepared DNA library amplicons
Genomic locations of interest
Design target sequences in
SureDesign
SureSelect Capture Library
Hybridize using SureSelect Capture Library
Capture Library/prepared DNA library hybrids
Capture hybrids on streptavidin-coated
magnetic beads
Captured,target-enriched DNA library
PCR amplify using Dual
Indexing primers
Dual-indexed, target-enriched DNA library
Pool libraries for multiplex sequencing
SureSelect-enriched dual-indexed NGS samples
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LTA was used to assess platelet function for seven patients and 
flow cytometry alone was performed for samples from 17 patients. 
Platelets from individuals with a borderline platelet count in PRP 
of between 0.1 and 0.15 × 109/L were assessed using both assays 
(n = 3). Platelet function studies revealed the suggestion of the pres-
ence of a secondary qualitative defect in addition to the reduction in 
platelet count in 19 of 24 (79%) (Table 1) of the overall cohort of pa-
tients tested.
3.2 | IT- specific NGS panel
On average, 326 variants were noted in samples from each individual 
analyzed by the IT- specific NGS panel. This ranged from 265 to 400 
variants across all samples analyzed. Following exclusion of synon-
ymous variants, an average of 73 variants, having a MAF ≤0.01 in 
the 1000- G database were noted per individual. When the ExAC 
database was interrogated for each of the variants identified in non 
UTR regions only those variants displayed in Table 3 were of a rare 
frequency (MAF <0.01).
Average coverage across the targeted regions was in excess of 
95% for all samples analyzed. An average read depth of 380 was 
noted at the site of each variation. This read depth was not observed 
below 121 at each point of all candidate variants and reached a fil-
tered read depth of 823.
3.3 | Validation of IT- specific NGS panel
Validation of the IT- specific NGS panel was performed by ana-
lyzing the panel’s sensitivity in detecting eight variants iden-
tified previously by WES analysis and confirmed by Sanger 
sequencing. Variants, at the time of validation, were likely 
candidate variants and include variants in genes not known 
previously to cause IT (see Table 2). All variants, excluding a 
previously identified frameshift causing insertion in TUBB1; 
c.1080_1081insG, p.Leu361Alafs*19 previously identified using 
WES in patient 31,12 were successfully identified, presum-
ably due to the sequence context around this genomic region. 
All known candidate variants tested were the only candidate 
variants following bioinformatics analysis of panel sequencing 
results in each patient.
3.4 | Candidate variants observed and variant 
prevalence in 31 new patients
In total, DNA samples from 31 new patients were analyzed by an 
IT- specific NGS panel. All patients, with the exception of 64, were 
single affected cases. Patient 64 forms part of a pedigree of four 
affected family members which will be discussed in more detail in 
the discussion section. Following post- sequencing bioinformatics 
analysis candidate variants previously implicated in IT genes were 
observed in 77% of individuals (Table 3). In total, 37 variants were 
noted in the 24 patients observed with a genetic variant in a gene 
previously known to cause IT. Seven patients were observed with 
two variants in two different genes and three patients were noted 
to have three variants. No patients were noted with two variants 
occurring within the same gene and all variants were observed in 
a heterozygous state. One variant; GP5; c.867G>C, p.Met289Ile, 
was noted in two unrelated patients, 57 and 58.
The majority of variants identified were missense variants affecting 
a single amino acid. This equated to 89% of the variants observed. In ad-
dition; one 5′UTR start gain was noted in patient 48 (TUBB1; c.- 88G>C), 
one frameshift causing deletion was noted in patient 50 (GP1BB; 
c.del120- 142, p.Arg42Cys fs*14), one stop loss variant was noted in pa-
tient 54 (GATA1; c.1240T>C, p.*414Arg+41), and one nonsense causing 
SNV was observed in patient 60 (ITGA2B; c.2176A>T, p.Lys726*).
Of the 37 variants, 11 (30%) were novel and not previously iden-
tified in any of the databases scrutinized. Twenty- six variants have 
been observed previously and the prevalence of these variants in 
the ExAC database, unless otherwise stated, is displayed in Table 3. 
When comparing all previously observed variants an average MAF 
of 0.00256 is noted. All variants were observed at a frequency of 
less than 0.01 and all previously identified variants, with the excep-
tion of rs111527738 which was present within the latest build of 
dbSNP. Four pathogenic or likely pathogenic variants were identi-
fied that are previously known to cause IT. These were found in pa-
tients; 54 (GATA1; c.1240T>C, p.*414Arg+41), 59 (RUNX1; c.386C>A, 
Patient Gene Variation Type
2 ANKRD26 c.- 126T>G 5′- UTR
17 RUNX1 c.G236A, pTrp79* Nonsense
20 RUNX1 c.G332A, p.Gly108Ser Partial heterozy-
gous missense
21 RUNX1 c.427 + 1G>T Splice site variant
26 SLFN14 c.A652G, p.Lys218Glu Missense
31 TUBB1 c.1080_1081insG, 
p.Leu361Alafs*19
Frameshift causing 
insertion
36 WAS c.G1456A, p.Glu486Lys X- linked Missense
41 ANKRD18A c.2395_2397del, p.Glu799del Non- frameshift 
causing deletion
TABLE  2 Eight patients and the eight 
known candidate variants12 representing a 
range of mutation types utilized for the 
validation of the IT- specific next- 
generation sequencing panel
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p.Ala129Glu), 70 (GFI1B; c.503G>T, p.Cys168Phe), and 64 (MYH9; 
c.2152C>T, p.Arg718Trp).3,15–17
Patient 54, a 12- year- old male with a history of cutaneous bleed-
ing and a mild reduction in platelet count (101 × 109/L) was noted 
with a stop loss variant in GATA1; c.1240T>C, p.*414Arg+41. The 
predicted effect of variation is a loss of the wild type stop codon and 
extension of the protein by 41 amino acids. Most reported variants 
within GATA1 occur within the N- terminal zinc finger domain, lead-
ing to a disruption of the binding of GATA1 to FOG1. The stop- loss 
variant noted in patient 54, was first identified in a 67- year- old male 
proband who suffers from easy bruising.16 The patient’s platelet 
counts varied between 86 to 94 × 109/L at different times of testing 
and no other differences in hematological cell numbers were noted. 
The patient was initially sequenced due to the presence of a rare X- 
linked blood group Lu(a- b- ) phenotype which results in the marked 
decrease in expression of Lutheran glycoprotein on the erythrocyte 
cell surface. To date, serological analysis using flow cytometry to 
analyze the presence of Lutheran on the erythrocyte cell surface 
has not been undertaken in patient 54. Also the presence of giant 
occasional macrothrombocytes, a marker of the published pheno-
type, have not been observed in patient 54 in routine histological 
examination.
A previously identified causative variant was noted in RUNX1 
in patient 59. The missense variant, c.386C>A, p.Ala129Glu, was 
found in addition to a missense variant in ITGA2B. The variant has 
previously been reported to be causative of FPD/AML in three pa-
tients from a single pedigree.15 All three patients were identified 
with the p.Ala129Glu germline mutation causative of FPD/AML. 
All patients developed AML as a result of a secondary somatic 
event occurring within RUNX1 progressing to patient death in all 
cases. Patient 59 is a male with a mild reduction in platelet count 
to 94 × 109/L. Following platelet function testing no reduction in 
platelet secretion (a hallmark of variants within RUNX1) was noted. 
However, it is highly likely that the variant observed in RUNX1 is 
causative of the hemostatic phenotype observed. Whether the 
variant within ITGA2B is additive to the phenotype is unlikely as 
the platelet count is considered mild in severity but may warrant 
further investigation.
Patient 64, is the only patient analyzed by the IT- specific panel 
for whom affected family members were also recruited to the study. 
The patient forms part of a pedigree of four affected family members 
with a shared phenotype and clinical symptoms. Following analysis 
of the IT- specific panel sequencing, a missense variant was identi-
fied in MYH9; c.2152C>T, p.Arg718Trp. This variant has been noted 
once previously in a patient initially diagnosed with MYH9- RD.3 The 
variant occurs within the motor domain of MYH9 and is associated 
with an increased risk of deafness and nephritis, however, no sec-
ondary symptoms have previously been reported in patient 64 or 
any of the affected family members also recruited to the UK- GAPP 
study. However patients such as this should be monitored regularly 
for signs of kidney disease. Two variants previously identified by 
WES analysis of 69 patients were also identified in patients analyzed 
by the IT- specific panel sequencing. These variants; CYCS; c.155C>T, 
p.Ala52Val, and ITGA2B; c.2176A>T, p.Lys726* were identified in pa-
tients 50 and 60, respectively.
3.5 | Conservation, pathogenicity prediction, and 
variant classification
Conservation at the site of variation was determined by PhyloP 
and PhastCons in silico software. Conservation scores for all vari-
ants occurring within known IT- causing genes in the 31 patients 
are shown in Table 3. Average scores of 3.32887 and 0.829571 
were observed across all variants in PhyloP and PhastCon analy-
sis, respectively. The majority of variants occurred at sites of high 
conservation and the two methodologies used were in agreement 
in all instances.
Pathogenicity was predicted using in silico prediction software 
as displayed in Table 3. Classification often varied amongst the soft-
ware used for each variant indicating the benign potential of the 
variants observed.
In total, of the 37 total variants noted across all patients investi-
gated, three variants were classified as “pathogenic” and five “likely 
pathogenic” when considering the ACMG consensus guidelines. The 
remaining 29 variants without a positive prediction of pathogenic-
ity were classified as of “unknown significance.” Only two variants 
displayed supporting evidence for a benign classification. Of the 24 
patients where a genetic variant was identified this classification 
predicted equated to 12% (3 of 24) of patients with a pathogenic 
variant, 21% (5 of 24) with a likely pathogenic variant, and 67% (16 of 
24) variants of unknown significance.
4  | DISCUSSION
An IT gene–specific NGS panel was developed in order to pre- screen 
patients prior to WES. The aim was to filter out patients with vari-
ants in known IT- causing genes allowing subsequent focus on WES 
for patients who may harbor variants in novel genes. In addition, the 
cost implications were an important consideration given that the 
WES was more than four times as expensive compared with targeted 
panel sequencing.
All sequencing passed QC at all points throughout sample 
preparation and QC, cluster density and overall sequencing data 
was sufficient when compared with routine sequencing using al-
ternate capture methods performed. Although considered a rapid 
capture method, Agilent SureSelectQXT sample preparation does 
not quite reach optimum depth of coverage, evenness and target 
enrichment when compared with alternate methods of capture 
including Agilent SureSelectXT.10,18 When applied to our custom 
designed panel, average coverage easily exceeded a universally 
accepted minimum 20x coverage for efficiently calling variants 
and an average read depth of 380 was identified at the points of 
variation.19
With a GC content of 73%, GP1BB often suffers from a reduction 
in coverage, which is why in WES analysis the gene was manually 
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TABLE  3 Variants identified by analysis of the IT- specific next- generation sequencing pane
Patient Gene(s) Genomic variation Protein effect Variation type Prevalence PhyloP
48 ABCG5 c.293C>G p.Ala98Gly Missense 0.005 (rs145154937) 5.277
ABCG8 c.1667T>C p.Phe556Ser Missense 0.0009 (rs548098742) 2.914
TUBB1 c.- 88G>C 5′UTR start gain 0.004 (1000G) (rs150072434)
49 ABCG5 c.1864A>G p.Met622Val Missense 0.00541 (rs140374206) −0.748
NBEAL2 c.6631G>A p.Asp2211Asn Missense Novel 5.515
50 CYCS c.155C>T p.Ala52Val Missense Novel 5.962
GP1BB c.del120- 142 p.Arg42Cys fs*14 Frameshift deletion Novel
51 FLI1 c.812G>A p.Arg271Gln Missense Novel 5.983
MYH9 c.2872G>A p.Ala958Thr Missense 0.0009 (rs151036570) 6.088
52 FLNA c.5948C>T p.Ser1983Leu Missense 0.0026 (rs187029309) 5.952
53 FLNA c.7583A>T p.Asp2528Val Missense Novel 4.858
MYH9 c.7C>G p.Gln3Glu Missense 0.0015 (rs56200894) 4.643
TUBB1 c.1199G>A p.Ser400Asn Missense Novel 5.88
54 GATA1 c.1240T>C p.*414Arg+41 Stop loss Known 2.408
55 GP1BA c.206C>T p.Pro69Leu Missense 0.001872 (rs138825640) −1.407
56 GP1BB c.242T>G p.Leu81Arg Missense Novel −0.162
57 GP5 c.867G>C p.Met289Ile Missense 0.003101 (rs142440028) 2.516
58 GP5 c.867G>C p.Met289Ile Missense 0.003101 (rs142440028) 2.516
STIM1 c.182A>G p.Glu61Gly Missense 0.00004941 (rs202160755) 2.851
59 ITGA2B c.886G>A p.Gly296Arg Missense Novel 3.205
RUNX1 c.386C>A p.Ala129Glu Missense Known (rs267607026) 6.077
60 ITGA2B c.2176A>T p.Lys726* Nonsense Novel 1.419
61 ITGA2B c.2417G>A p.Ser806Asn Missense Novel 0.148
WAS c.995T>C p.Val332Ala Missense 0.0051 (rs2737799) 0.096
62 MKL1 c.569C>T p.Pro190Leu Missense 0.00016 (rs200309955) 3.693
63 MKL1 c.1492G>C p.Val498Leu Missense 0.000008638 (rs199750225) 2.138
64 MYH9 c.2152C>T p.Arg718Trp Missense Known 2.044
65 MYH9 c.5074G>A p.Ala1692Thr Missense Novel 4.087
66 MYH10 c.2987C>T p.Ala965Val Missense 0.0079 4.822
NBEAL2 c.4361C>T p.Thr1454Met Missense 0.0001 3.227
67 TUBB1 c.421G>A p.Gly141Arg Missense 0.00003295 (rs778975827) 5.803
68 ABCG8 c.1629G>T p.Arg543Ser Missense 0.0002 (rs201690654) 5.057
69 ACTN1 c.136C>T p.Arg46Trp Missense 0.00000827 5.532
70 GFI1B c.503G>T p.Cys168Phe Missense 0.0006011 (rs527297896) 4.334
71 RUNX1 c.86T>C p.Leu29Ser Missense 0.01629 (rs111527738) 0.683
NBEAL2 c.4085G>A p.Arg1362Gln Missense 0.00000829 1.666
GFI1B c.551G>C p.Arg184Pro Missense 0.00000746 1.433
72–78 Unknown
(Continued)
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Patient Phastcons Mutation taster PolyPhen- 2 SIFT Provean ACMG criteria Classification
48 1 D D D D PP3 Uncertain significance
1 D D D D PP3 Uncertain significance
Uncertain significance
49 0 P B T N BP4 Uncertain significance
0.997 D D D D PM2, PP3 Uncertain significance
50 1 D B D D PM2 Uncertain significance
D PM2, PP3, PM4, PP4 Likely pathogenic
51 1 D D D D PM2, PP3 Uncertain significance
1 D B T N Uncertain significance
52 1 P D D D Uncertain significance
53 1 D D D D PM2, PP3, Uncertain significance
0.998 D B D N Uncertain significance
0.972 D B D N PM2 Uncertain significance
54 0.572 P PM4, PS1, PP5 Likely pathogenic
55 0 P B D D Uncertain significance
56 0.175 P D D D PM2, PP4 Uncertain significance
57 0.55 P B D D Uncertain significance
58 0.55 P B D D Uncertain significance
1 D B D D Uncertain significance
59 0.999 D B D D PM2 Uncertain significance
1 D D D D PP3, PS1, PS3 Pathogenic
60 0.957 D PM2, PM4, PVS1, PP4 Pathogenic
61 0.286 P B T N PM2 Uncertain significance
0 P B T N BP4 Uncertain significance
62 0.987 D B T D Uncertain significance
63 0.998 D B T N Uncertain significance
64 1 D D D D PP3, PS1, PS3, PM 
(segregation), PP4
Pathogenic
65 1 D B T N PM2 Uncertain significance
66 1 D B D D Uncertain significance
0.999 D B T N Uncertain significance
67 1 D D D D PP3 Uncertain significance
68 1 D D D N PM2 Uncertain significance
69 1 D D D D PS1, PM2, PP3 Likely pathogenic
70 1 D D D D PS1, PM2, PP3 Likely pathogenic
71 1 P D T N Uncertain significance
1 P D T N Uncertain significance
0.995 D D D D PS1, PM2, PP3 Likely pathogenic
72–78 N/A
Prevalence is shown in the ExAC consortium if not specified otherwise. PhyloP and Phastcons scores are shown. Variants are noted as D, disease 
causing and P, polymorphism in MutationTaster; D, damaging and T, tolerated in SIFT; D, deleterious and N, neutral in Provean; D, damaging and 
B, benign in PolyPhen- 2 in silico pathogenicity prediction software. PhyloP scores vary between −14 and +6 and measure conservation at each 
individual base, sites predicted to be conserved are assigned a positive score, fast- evolving sites are assigned a negative score. Mutationtaster 
uses a Beyes classifier to predict the effect of a mutation from a feed a classifiers. SIFT damaging prediction score = <0.05. Provean deleterious 
score = < −2.5. PolyPhen- 2 predictions are appraised qualitatively as benign or damaging. The ACMG consensus guidelines, including supporting 
evidence, are also shown.
TABLE  3  (Continued)
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analyzed. Utilizing the NGS panel there was no drop in coverage 
within GP1BB for all patients analyzed and two variants, in patients 
50 and 56, were identified, which may be causative of disease. This 
represents variants which could be potentially missed by other se-
quencing methodologies and potential advantage of panel- based 
sequencing.
In total, candidate variants, that could be considered for fur-
ther analysis, were identified in 77% of individuals when analyzed 
by the IT- specific panel. This detection rate is in keeping with 
other recent previous large- scale targeted panel sequencing stud-
ies and the application of WES to patients with IT of unknown eti-
ology.4,12,20,21 One possible explanation for the inflated detection 
rate for panel based platforms is the relative increase in average 
read coverage when compared to WES analysis, especially at the 
point of variation.
When comparing prevalence, however, next- generation panel se-
quencing identifies a large number of variants that have been previ-
ously identified with a low MAF. This may be an indication that the 
variants are tolerated within the population and are not causative 
of disease. One way to determine this would be to analyze the co- 
segregation of variants within affected/unaffected relatives of the 
index cases. This has the potential to rule out or further strengthen 
any identified variants but unfortunately in this study this information 
was unavailable. The most comprehensive database of genetic vari-
ation is noted to be the ExAC database,22 which includes data from 
the aggregation and analysis of high- quality exome sequence data 
for 60 706 individuals of diverse ancestries generated as part of the 
Exome Aggregation Consortium (ExAC). It is plausible, therefore, that 
although the variants have previously been noted, they are causative 
of a mild reduction in platelet count that has, or has not, been previ-
ously diagnosed in all other patients with the shared variant. To de-
termine the reality of this would require further conformational work.
Comparing pathogenicity prediction and variant classification to 
the variants determined by WES analysis, a larger percentage of vari-
ants were deemed to be of unknown significance. This may reflect a 
reduced rate of sensitivity and a higher proportion of false negative 
variants identified. However, it is worth considering that the ma-
jority of variants, 62% (23 of 37), displayed supporting evidence of 
pathogenicity but lacked sufficient evidence to be classified as such. 
This could potentially be an indication of the lack of strengthening 
evidence that is normally provided in the form of related affected 
family members that would be recruited to the study, negatively af-
fecting classification because of a lack of segregation analysis.
The presence of a variant in MYH9 in patient 64 highlights 
the difficulty of picking up such defects despite the routine 
pre- screening for disorders such as BSS- and MYH9- related 
disease (using flow cytometry or the presence of granulocyte 
inclusions, respectively) in hemophilia care centers before re-
cruitment to the UK- GAPP study. This was also the case in our 
previous study where we employed WES and detected MYH9 
and BSS defects despite pre- screening by the referring labora-
tories.12 Analyzing patients using the IT- specific panel has eluci-
dated variants in genes known to cause BSS- and MYH9- related 
disease in seven patients. With the exception of patients 50 
and 65, who present with the characteristic increase in MPV 
to the magnitude of observable giant platelets, the remaining 
patients show an unaltered MPV. No Döhle- like body leukocyte 
inclusions were noted on peripheral blood smears of patients 
64 and 65 and no patients presented with secondary symptoms 
relating to specific IT disorders. However it should be noted 
that not all MYH9 defects are associated with the presence 
of Dohle- like bodies in a peripheral blood smear. The defects 
identified may therefore be causative of non- typical forms of 
BSS- and MYH9- related IT but in order to exclude a MYH9 de-
fect conclusively, immunofluorescence should be performed 
for the non- muscle myosin heavy chain protein.
A phenotype- genotype correlation is often utilized in aiding 
in the diagnosis of a patients disease. Patient 61 presented with 
a marked reduction in the cell surface levels of CD41, the inte-
grin alpha IIb, to around 50% of the levels observed compared 
to the travel control tested simultaneously. When analyzed by 
the IT- specific NGS panel a missense variant was identified in 
ITGA2B. This variant, c.2417G>A, p.Ser806Asn, is novel within 
all databases but predicted benign and not well conserved at 
the site of variation. The variant occurs within the extracellu-
lar domain and the integrin alpha IIb heavy chain. Although not 
predicted to, the reduction in cell surface CD41 is indicative of 
the possibility that the variant in ITGA2B affects either protein 
levels or cellular localization potentially leading to the observed 
platelet- based bleeding phenotype. This is the only occurrence 
of a genotype- phenotype correlation in all patients analyzed by 
the IT- specific NGS panel. Although three variants were identi-
fied in ITGA2B and one variant was identified in GP1BA , none of 
the patients, with the exception of 61, were observed to have 
a reduction in the corresponding cell surface receptor levels.
Interestingly a reduction in cell surface expression of CD42b, 
encoded by GP1BA, was noted in patient 50, who harbors a poten-
tially deleterious large deletion of GP1BB that spans two previously 
reported disease- causing variants.23,24 Although not occurring in 
the encoded gene, the variant, due to the detrimental effect of a 
frameshift causing deletion, may have propensity to disrupt the sta-
bility of the receptor complex leading to a reduction in cell surface 
expression.
As with variants determined by WES analysis, the variants ob-
served following the application of the IT- specific NGS panel require 
further conformational work to be determined disease causing. 
Further work would focus around this point mainly, utilizing many of 
the biomarkers of disease attributed to variants in certain genes and 
recruiting related affected family members of previously analyzed 
patients. This will strengthen any initial genetic variants that may be 
indicative of disease through segregation analysis but it also has the 
propensity to spread disease awareness of an under recognized and 
under- diagnosed genetic disorder.
A possible lack of genotype–phenotype correlation shown in 
patients harboring variants in ITGA2B, GP1BA, and MYH9 in par-
ticular is an interesting observation, however, further work would 
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be needed to validate this. The possibility that these variants are 
disease causing rests on the functional confirmation of the effect 
of variation. However, if causative, the patients represent a unique 
subset of each individual disease that does not share the typical 
phenotypic presentation of previous cases. The likelihood that pa-
tients exist without the secondary symptoms and qualitative de-
fects in platelet function attributed to these disorders is therefore 
relatively high.
Seven patients in total were observed without any variants in 
genes of the IT- specific panel. The sequencing panel employed did 
not look at Copy Number Variations (CNVs) which could be present in 
the remaining patients studied. Due to the absence of variants within 
the panel of 30 genes, there is a high chance that the genetic etiology 
of disease is due to variants in novel genes not previously implicated 
in IT. Analysis of these patients in particular may progress our cur-
rent knowledge of IT through the determination of novel causative 
genes.25
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